During the past decade, Genoscience Pharma conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Genoscience Pharma" are "COVID-19" (1 trials) and "Primary Liver Cancer" (1 trials). Many other conditions were trialed in "Genoscience Pharma" in a lesser frequency.

Most popular intervention types in "Genoscience Pharma" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "GNS561" (1 trials) and "GNS561 oral tablets and capsules" (1 trials). Other intervention names were less common.

The vast majority of trials in "Genoscience Pharma" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Genoscience Pharma". 1 are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Genoscience Pharma, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Genoscience Pharma, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".